news flash·2025-07-11 08:45Core Viewpoint - Fosun Pharma's subsidiary, Shanghai Chaohui Pharmaceutical Co., Ltd., has received acceptance from the National Medical Products Administration for the drug registration application of Compound Polyethylene Glycol Electrolyte Powder (II), which is intended for bowel preparation prior to colonoscopy, barium enema X-ray imaging, and colorectal surgery [1] Group 1 - The drug is aimed at facilitating the clearance of intestinal contents before medical procedures [1] - By May 2025, Fosun Pharma's total R&D investment for the series of Compound Polyethylene Glycol Electrolyte Powder, including this drug, is expected to reach approximately RMB 4.74 million [1] - In 2024, the projected sales revenue for Compound Polyethylene Glycol Electrolyte Powder (II) in mainland China (excluding Hong Kong, Macau, and Taiwan) is estimated to be around RMB 307 million [1]